Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

358 ARTÍCULOS , VIENDO DEL 211 AL 225

Alzheimer's Disease Risk and Progression: The Role of Nutritional Supplements and their Effect on Drug Therapy Outcome

Giulietti A, Vignini A, Nanetti L, Mazzanti L, Di Primio R, Salvolini E.

Curr Neuropharmacol. 2016;14(2):177-90. doi: 10.2174/1570159x13666150928155321.

Recent Updates on the Association Between Alzheimer's Disease and Vascular Dementia

Ashraf GM, Chibber S, Mohammad, Zaidi SK, Tabrez S, Ahmad A, Shakil S, Mushtaq G, Baeesa SS, Kamal MA.

Med Chem. 2016;12(3):226-37. doi: 10.2174/1573406411666151030111820.

Alterations in Glucose Metabolism on Cognition: A Possible Link Between Diabetes and Dementia

González-Reyes RE, Aliev G, Ávila-Rodrigues M, Barreto GE.

Curr Pharm Des. 2016;22(7):812-8. doi: 10.2174/1381612822666151209152013.

Atorvastatin May Correct Dyslipidemia in Adult Patients at Risk for Alzheimer's Disease Through an Anti-Inflammatory Pathway

Zhao L, Zhao Q, Zhou Y, Zhao Y, Wan Q.

CNS Neurol Disord Drug Targets. 2016;15(1):80-5. doi: 10.2174/1871527315999160111160143.

Effect of Amyloid Imaging on the Diagnosis and Management of Patients with Cognitive Decline: Impact of Appropriate Use Criteria

Grundman M, Johnson KA, Lu M, Siderowf A, Dell'Agnello G, Arora AK, Skovronsky DM, Mintun MA, Pontecorvo MJ; 18F-AV-45-A17 Study Group.

Dement Geriatr Cogn Disord. 2016;41(1-2):80-92. doi: 10.1159/000441139. Epub 2016 Jan 8.

Heterogeneity of Treatment Response to Citalopram for Patients With Alzheimer's Disease With Aggression or Agitation: The CitAD Randomized Clinical Trial

Schneider LS, Frangakis C, Drye LT, Devanand DP, Marano CM, Mintzer J, Mulsant BH, Munro CA, Newell JA, Pawluczyk S, Pelton G, Pollock BG, Porsteinsson AP, Rabins PV, Rein L, Rosenberg PB, Shade D, Weintraub D, Yesavage J, Lyketsos CG; CitAD Research Group.

Am J Psychiatry. 2016 May 1;173(5):465-72. doi: 10.1176/appi.ajp.2015.15050648. Epub 2016 Jan 15.

Interaction between cerebrovascular disease and Alzheimer pathology

Saito S, Ihara M.

Curr Opin Psychiatry. 2016 Mar;29(2):168-73. doi: 10.1097/YCO.0000000000000239.

Memantine Exacerbates Corrected QT Interval Prolongation in Alzheimer's Disease: A Case Report from an Unintentional Rechallenge

Kajitani K, Yanagimoto K, Monji A, Maruyama T.

J Am Geriatr Soc. 2016 Jan;64(1):232-3. doi: 10.1111/jgs.13897.

Emerging amyloid disease-modifying drugs for Alzheimer's disease

Galimberti D, Scarpini E.

Expert Opin Emerg Drugs. 2016;21(1):5-7. doi: 10.1517/14728214.2016.1146678. Epub 2016 Feb 15.

Nicotinic Acetylcholine Receptors in the Pathophysiology of Al zheimer's Disease: The Role of Protein-Protein Interactions in Current and Future Treatment

Thomsen MS, Andreasen JT, Arvaniti M, Kohlmeier KA.

Curr Pharm Des. 2016;22(14):2015-34. doi: 10.2174/1381612822666160127112357.

Classification of Neuropsychiatric Symptoms Requiring Antipsychotic Treatment in Patients with Alzheimer's Disease: Analysis of the CATIE-AD Study

Nagata T, Shinagawa S, Nakajima S, Plitman E, Mihashi Y, Hayashi S, Mimura M, Nakayama K.

J Alzheimers Dis. 2016;50(3):839-45. doi: 10.3233/JAD-150869.

Pharmacotherpy and Alzheimer's Disease: The M-Drugs (Melatonin, Minocycline, Modafinil, and Memantine) Approach

Daulatzai MA.

Curr Pharm Des. 2016;22(16):2411-30. doi: 10.2174/1381612822666160203142111.

Predictors of cognitive decline and treatment response in a clinical trial on suspected prodromal Alzheimer's disease

Teipel SJ, Cavedo E, Grothe MJ, Lista S, Galluzzi S, Colliot O, Chupin M, Bakardjian H, Dormont D, Dubois B, Hampel H; Hippocampus Study Group.

Neuropharmacology. 2016 Sep;108:128-35. doi: 10.1016/j.neuropharm.2016.02.005. Epub 2016 Feb 10.

Amyloid PET Screening for Enrichment of Early-Stage Alzheimer Disease Clinical Trials: Experience in a Phase 1b Clinical Trial

Sevigny J, Suhy J, Chiao P, Chen T, Klein G, Purcell D, Oh J, Verma A, Sampat M, Barakos J.

Alzheimer Dis Assoc Disord. 2016 Jan-Mar;30(1):1-7. doi: 10.1097/WAD.0000000000000144.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias